In April 2025, the U.S. Food and Drug Administration (FDA) released a landmark guidance titled “Roadmap to Reducing Animal Testing in Preclinical Safety Studies,” outlining its commitment to advancing New Approach...more
Artificial intelligence (AI) has transformed scientific research and innovation, yet as previously discussed, the Polanyi Paradox remains a significant obstacle to using AI to generate creative solutions or breakthrough...more
On January 6, 2025, the U.S. Food and Drug Administration (FDA) released draft guidance titled Considerations for the Use of Artificial Intelligence To Support Regulatory Decision-Making for Drug and Biological Products...more
1/16/2025
/ Artificial Intelligence ,
Clinical Trials ,
Compliance ,
Digital Health ,
Draft Guidance ,
Food and Drug Administration (FDA) ,
Intellectual Property Protection ,
Machine Learning ,
Patents ,
Pharmaceutical Industry ,
Popular ,
Regulatory Requirements ,
Risk Management ,
Trade Secrets
The use of artificial intelligence (AI) to advance stem cell therapy has produced exciting results, with a key role in driving recent growth and innovation. Separated into three parts, this article provides an overview the...more
10/24/2023
/ Alice/Mayo ,
Artificial Intelligence ,
Biotechnology ,
Innovation ,
Intellectual Property Protection ,
Inventions ,
Patent Act ,
Patent Trial and Appeal Board ,
Patent-Eligible Subject Matter ,
Safeguards Rule ,
Stem cells
The rapid development of artificial intelligence (AI) systems will significantly impact businesses that rely on genomic data analysis for research and development of therapeutics and diagnostic decision-making. This article...more
A major step forward in using Artificial Intelligence (AI) for scientific discovery in the field of stem cell research was recently reported, reflecting the continued growth of the technology and stressing the need for...more